IMNN Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: The Motley Fool

Imunon (IMNN) Q3 2025 Earnings Call Transcript

a month ago - By: Imunon, Inc.

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Imunon, Inc.

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

a month ago - By: Imunon, Inc.

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer

4 months ago - By: Benzinga - Mentions: AFG CXDO YUM PACK ...

Earnings Scheduled For August 5, 2025

4 months ago - By: Benzinga

Insights into Imunon's Upcoming Earnings

5 months ago - By: Stocktwits - Mentions: VXF

Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued

5 months ago - By: Imunon, Inc.

IMUNON Announces Reverse Stock Split

a month ago - By: Imunon, Inc.

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

a month ago - By: Imunon, Inc.

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

a month ago - By: Imunon, Inc.

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

2 months ago - By: Imunon, Inc.

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

2 months ago - By: Imunon, Inc.

IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

2 months ago - By: Imunon, Inc.

IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences

2 months ago - By: Imunon, Inc.

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

3 months ago - By: Imunon, Inc.

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

3 months ago - By: Imunon, Inc.

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

3 months ago - By: Imunon, Inc.

IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

4 months ago - By: Imunon, Inc.

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

4 months ago - By: Imunon, Inc.

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

4 months ago - By: Imunon, Inc.

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

5 months ago - By: Imunon, Inc.

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

5 months ago - By: Imunon, Inc.

IMUNON Announces Stock Dividend Boosting Shareholder Value

5 months ago - By: Imunon, Inc.

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

6 months ago - By: Imunon, Inc.

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

6 months ago - By: Imunon, Inc.

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

6 months ago - By: Virtual Investor Conferences - Mentions: NIKA TIVC ADIA STSS ...

IMUNON INC (IMNN) Stock News

IMNN Latest News, Press Relases and Analysis

Imunon (IMNN) Q3 2025 Earnings Call Transcript

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer

Earnings Scheduled For August 5, 2025

Insights into Imunon's Upcoming Earnings

Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued

IMUNON Announces Reverse Stock Split

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

IMUNON Announces Stock Dividend Boosting Shareholder Value

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Life Sciences Investor Forum: Now Available for Online Viewing